A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

NCT ID: NCT06698003

Last Updated: 2025-03-04

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 134 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-15
• Study Completion Date: 2029-11-15

Brief Summary

The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.

Conditions

T-Cell Leukemia/Lymphoma, Adult; T-cell Leukemia/Lymphoma; T-cell Leukemia; Lymphoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1

Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses

Group Type: EXPERIMENTAL

Mogamulizumab

Intervention Type: DRUG

Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses

Cohort 2

Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses

Group Type: EXPERIMENTAL

Mogamulizumab

Intervention Type: DRUG

Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses

Interventions

Mogamulizumab

Cohort 1: 0.3 mg/kg of mogamulizumab every 12 weeks, for 2 total doses Cohort 2: 0.3 mg/kg of mogamulizumab every 6 weeks, for 4 total doses

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Screening Cohort (US patients only):

• Age ≥18 years when informed consent is obtained
• Has freely given written informed consent to participate in the study

Treatment Cohorts (Cohorts 1 and 2):

• Positive for anti-HTLV-1 antibody in the serum using an FDA approved assay for US patients (Avioq HTLV-I/II Microelisa System). UK patients should use UK Accreditation Service (UKAS) accredited tests, Abbot Architect ELISA Serology Screening assay and confirmatory serology Western Blot (performed at Public Health England, Virus Ref Dept, Colindale).
• High-risk phenotype (PVL≥8% of PBMC)
• Age ≥18 years when informed consent is obtained
• Primary organ functions are stable

• Neutrophil count: ≥ 1000/mm3, unless patient has diagnosis of ethnic neutropenia
• Platelets: ≥100,000/mm3
• Hemoglobin: ≥9.0 g/dL
• Serum aspartate aminotransferase (AST): ≤1.5x upper limit of normal (ULN)
• Alanine aminotransferase (ALT): ≤1.5x ULN
• Total bilirubin: ≤1.5x ULN
• Serum creatinine (Cr): ≤1.5x ULN
• Blood oxygen saturation (SpO2): ≥90%
• Electrocardiogram (ECG): No abnormal findings requiring treatment are observed
• Has freely given written informed consent to participate in the study
• For females of reproductive potential: use of effective contraception during treatment and for at least 3 months after completion of mogamulizumab therapy. For males who have sexual intercourse with females of reproductive potential: use of effective contraception during treatment and for at least 3 months after completion of mogamulizumab therapy.

Exclusion Criteria

In order to protect subjects and avoid any problems in evaluating the study drug, patients who meet any of the following criteria should be excluded from enrollment in the study, in either screening or treatment cohorts:

• Patients with a history of any of the following:

• Neutrophil count: ≤1000/mm3, unless patient has diagnosis of ethnic neutropenia
• Acute or chronic hepatitis or hepatic cirrhosis, other than patients with positive antibodies and negative PCR as noted in criteria #11 and #12 below.
• Tuberculosis or with active tuberculosis
• Myocardial infarction within 12 months prior to the date of enrollment
• Allergic reaction to administration of antibody drug products
• Other cancers. Patients with a history of a localized solid tumor who received definitive, curative treatment and who have been without evidence of disease for 5 years prior to enrollment will be able to enroll in the study. Patients with radically resected basal cell carcinoma of the skin, squamous cell carcinoma (except malignant melanoma), noninvasive cervix carcinoma, carcinoma in situ in the gastrointestinal tract or corpus of the uterus, localized thyroid cancer, and localized renal cell carcinoma will be able to enroll in the study if they are determined to be completely cured, even if within 5 years of enrollment.
• Prior treatment with immunosuppressants or interferon alpha products within 6 months prior to the date of enrollment
• Serious complications (heart failure, lung disease, renal failure, hepatic failure, uncontrolled diabetes mellitus, etc.)
• History of an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
• Any ailment that could be exacerbated by the administration of KW-0761, in the judgment of the Principal Investigator or co-Investigator
• Diagnosis of ATL
• Women who are pregnant, breastfeeding, who may be pregnant, or wish to bear children while receiving treatment or within 3 months of last dose of mogamulizumab
• Patients who have taken multivitamins (Alinamin, vitamin C, etc.) or supplements such as fucoidan, catechin, and pentosan polysulfate within 2 weeks prior to the date of enrollment
• Prior treatment with other study drugs within 4 months prior to giving informed consent
• Complications of spinal cord compressive lesions such as cervical spine disease, disc herniation, and ossification of the yellow ligament
• Uncontrolled psychiatric disorder, epilepsy, or dementia
• Positive test for Hepatitis B surface antigen or HBV-DNA (using real-time PCR). Positive Hepatitis B core antibody is permitted if HBV-DNA PCR is negative and the patient remains on prophylaxis during study.
• Positive test for Hepatitis C virus antibody, unless Hepatitis C PCR is negative.
• Positive test for HIV antibody, unless undetectable HIV RNA > 6 months and CD4 within normal limits per institutional standard.
• Patients considered unqualified to participate in the study by the Principal Investigator or co-Investigator

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Steven Horwitz, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Memorial Sloan Kettering at Basking Ridge (All protocol activities)

Basking Ridge, New Jersey, United States

Site Status: RECRUITING

Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, United States

Site Status: RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States

Site Status: RECRUITING

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities)

Commack, New York, United States

Site Status: RECRUITING

Memorial Sloan Kettering Westchester (All protocol activities)

Harrison, New York, United States

Site Status: RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

Site Status: RECRUITING

Memorial Sloan Kettering Nassau (All protocol activities)

Uniondale, New York, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Steven Horwitz, MD

Role: CONTACT

horwitzs@MSKCC.ORG

646-608-2680

Alison Moskowitz, MD

Role: CONTACT

moskowia@mskcc.org

646-608-3726

Facility Contacts

Steven Horwitz, MD

Role: primary

646-608-2680

Steven Horwitz, MD

Role: primary

646-608-2680

Steven Horwitz, MD

Role: primary

646-608-2680

Steven Horwitz, MD

Role: primary

646-608-2680

Steven Horwitz, MD

Role: primary

646-608-2680

Steven Horwitz, MD

Role: primary

646-608-2680

Steven Horwitz, MD

Role: primary

646-608-2680

Related Links

http://www.mskcc.org

Memorial Sloan Kettering Cancer Center

Other Identifiers

21-486

Identifier Type: -

Identifier Source: org_study_id